

The Angiogenesis Foundation Presents the 6th Annual International

**M. Judah Folkman Conference**

**Antiangiogenesis  
New Frontiers in Therapeutic Development**

October 13-14, 2008

President's Ballroom  
Hyatt Regency Cambridge, Massachusetts

**Conference Chair:**  
William W. Li, M.D.  
The Angiogenesis Foundation

*PRELIMINARY PROGRAM*

**DAY ONE**

7:00 *Registration and Buffet Breakfast*

7:45 **Welcome and Introduction**

**Opening Keynote**

8:00 Folkman's Legacy: New Directions in Antiangiogenesis  
**William W. Li, M.D.**, The Angiogenesis Foundation

**SESSION I: New Targets and Strategies**

8:45 Platelet biomarkers in cancer: useful for diagnosis or monitoring therapy  
**Giannoula Klement, M.D.**, Dana-Farber Cancer Institute

9:15 Factors regulating the regression of angiogenic vessels  
**Andrius Kauzlasikas, Ph.D.**, Schepens Eye Institute

9:45 Discovery of novel gene and protein targets expressed in tumor blood vessels  
**Nancy Klauber-DeMore, M.D.**, University of North Carolina at Chapel Hill

10:15 *Networking Refreshment Break*

10:45 Vaccines targeting the tumor vasculature as cancer therapy  
**Samir N. Khleif, M.D.**, U.S. National Cancer Institute Cancer Vaccine Section

11:15 RGS5: A quantitative marker of vascular stability and validation of a combination therapy strategy for anti-angiogenesis  
**Eric Yin-Shan Ng, Ph.D.**, Pervasis Therapeutics, Inc.

**11:45 Moderated Panel Discussion and Q&A**

12:15 *Networking Luncheon*

1:45 Control the angiogenic switch by endothelial progenitor cells: implications for cancer biology and therapy

**Vivek Mittal, Ph.D.**, Cornell University Medical Center

2:15 Mechanisms for HIF-1-independent angiogenic progression

**Zoltan Arany, M.D., Ph.D.**, Beth Israel Deaconess Medical Center

2:45 An antiangiogenic nanotechnology strategy for suppressing cancer metastases

**Ofra Benny, Ph.D.**, Children's Hospital Boston

3:15 New tumor targets from human endothelial cells

**Beverly A. Teicher, Ph.D.**, Genzyme Corporation (Invited)

3:45 *Networking Refreshment Break*

4:15 Ligand-directed targeted therapy and molecular imaging of tumor vasculature

**Wadih Arap, M.D., Ph.D.**, The University of Texas M.D. Anderson Cancer Center

**4:45 Moderated Panel Discussion and Q&A**

5:15 *Networking Cocktail Reception*

**DAY TWO**

7:00 *Registration and Buffet Breakfast*

7:45 Summary of Day 1 and Day 2 Opening Remarks

**SESSION II: CLINICAL DEVELOPMENT**

8:00 Multikinase and other antiangiogenic strategies in primary liver cancer

**Andrew X. Zhu, M.D., Ph.D.**, Massachusetts General Hospital

8:30 Challenges in optimizing antiangiogenic therapy for breast cancer

**Erica L. Mayer, M.D., M.P.H.**, Dana Farber Cancer Institute

9:00 Development of vascular disrupting agents and their use in combination with antiangiogenic therapies

**Dai Chaplin, Ph.D.**, OXiGENE

9:30 Validating antiangiogenic therapy in pancreatic cancer

**George A. Fisher, M.D., Ph.D.**, Stanford University School of Medicine

- 10:00 Impact of chemotherapy on targeted therapy in non-small cell lung cancer: the way forward  
**Alex Adjei, M.D., Ph.D.**, Roswell Park Cancer Institute
- 10:30 *Networking Refreshment Break*
- 11:00 Endpoints and markers for antiangiogenic therapy in malignant glioma  
**Tracy Batchelor, M.D., M.P.H.**, Massachusetts General Hospital
- 11:30 The VHL tumor suppressor gene: angiogenesis and kidney cancer  
**William Kaelin, M.D.**, Dana Farber Cancer Institute
- 12:00 **Moderated Panel Discussion and Q&A**
- 12:30 *Networking Luncheon*
- 1:45 Antiangiogenesis for adjuvant therapy in early stage colorectal cancer  
**Al Benson III, M.D.**, Northwestern University
- 2:15 Anti-VEGF therapy and the kidney  
**Susan E. Quaggin, M.D.**, University of Toronto
- 2:45 Evaluation of the cardiovascular effects of tyrosine kinase therapy  
**Ming Hui Chen, M.D.**, Children's Hospital Boston
- 3:15 *Brief Refreshment Break*
- 3:30 Predictive genes for response to VEGFR tyrosine kinase inhibition  
**Peter M. Wilson, Ph.D.**, University of Southern California
- 4:00 **Moderated Panel Discussion and Q&A**
- FUTURE OF MEDICINE LECTURE**
- 4:30 Antiangiogenesis: emerging paradigms  
**Rakesh Jain, Ph.D.**, Massachusetts General Hospital
- 5:15 Closing Remarks
- 5:30 Close of Conference